As the year draws to a close, we have been reflecting on the events at Isogenica over the last quarter. We’ve had a busy few months….

This edition we’re talking blood cancer for September’s awareness month and discussing the benefits of bi-specific antibodies in tackling blood cancers.

Not many Biotechs get to turn 25, but this month at Isogenica we are celebrating our quarter century! This edition we look back through our 25 years of new technologies, acknowledging our wonderful partnerships….

This edition we’re talking synthetic libraries: read on to see how we can save up to 8 months on immunisation alone compared with traditional approaches. Since November we’ve seen Dave attend Genesis in London, Ben go to PEGS, Barcelona, and Marion off to CAR-T, London….

We’re experts on VHH antibodies. Read on to discover the advantages of using VHHs in CAR targeting, our recently launched ISOXTEND® technology, and how our VHHs are being tested in a potential new therapy for heart failure…

Immunotherapy has transformed the cancer treatment landscape in recent years, harnessing the power of the immune system to target cancer cells. However, checkpoint inhibitor drugs don’t work for all patients, so the hunt is on for more targeted and personalised therapies that directly engage immune cells with cancer cells.

Introducing VHHantage™ allowing maximised diversity humanised VHH binders with significantly reduced liabilties, allowing the efficient discovery developable antibodies.

Isogenica have developed fully synthetic, in vitro plug­and­play cassette­based approach to efficiently generate combinations of bi­ and tri­specific VHH, exemplified in in vitro studies.

Tune in to hear Isogenica’s CSO Dr Bill Eldridge describe applications of naturally monovalent antibody domain structure combined to generate the next generation of multi-specific biologics.